Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
Wungki Park, Anup Kasi, Alexander I Spira...
https://pubmed.ncbi.nlm.nih.gov/41879829/Actively Recruiting
Led by Astellas Pharma Inc · Updated on 2026-10-14
681
Participants Needed
68
Research Sites
N/A
Total Duration
Researchers are evaluating ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. This Phase 1 open-label study aims to assess how safe and tolerable ASP3082 is when given alone or with other treatments like cetuximab. The study includes people who have received prior standard therapies or are ineligible for them, focusing on determining appropriate doses and treatment combinations. The study is divided into two parts. In Part 1, small groups of participants receive increasing doses of ASP3082 alone or with cetuximab through intravenous infusion in 21-day cycles to find suitable dosing levels. In Part 2, participants receive ASP3082 alone or combined with other therapies such as FOLFIRINOX, Nab-paclitaxel plus gemcitabine, docetaxel, pembrolizumab, platinum-based chemotherapy with pemetrexed, or NALIRIFOX, with dosing based on Part 1 findings. Treatment continues until intolerable side effects, disease progression, starting other cancer treatments, or participant decision to stop. Participants will undergo regular assessments including monitoring for side effects, laboratory tests, electrocardiograms, physical exams, and performance status evaluations for up to 48 months. Researchers will measure dose-limiting toxicities, adverse events, and tumor response using standard criteria. Tumor samples will be collected before and during treatment to assess KRAS G12D changes. The study monitors safety and treatment effects closely throughout participation, which may last several years.
CONDITIONS
A Study of ASP3082 in Adults With Advanced Solid Tumors
A
Astellas Pharma Global Development, Inc.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Astellas Pharma Inc
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Setidegrasib (ASP3082) Monotherapy and Combination Regimens | Current Standard Chemotherapy Regimens for KRAS G12D-Mutant Advanced Solid Tumors |
|---|---|---|
| What each regimen is | Setidegrasib (ASP3082), a selective KRAS G12D inhibitor, administered as monotherapy or combined with drugs such as cetuximab, chemotherapy agents, or immunotherapy in advanced solid tumor cohorts. Regimens span dose escalation, expansion, and combination therapy, including pancreatic cancer and NSCLC subgroups. | Standard-of-care chemotherapy regimens include FOLFIRINOX or nab-paclitaxel plus gemcitabine for pancreatic cancer and platinum doublet chemotherapy (cisplatin or carboplatin plus pemetrexed or docetaxel) for advanced non-small cell lung cancer. These regimens are guideline-recommended for KRAS-mutant malignancies. |
| Role in study or patient care | ASP3082 regimens are directly assigned as investigational therapy in the single-group trial across dose escalation/expansion and combination therapy cohorts for KRAS G12D-mutant solid tumors. | Standard chemotherapy is prescribed as the current treatment outside the trial for eligible patients at similar disease stage, serving as first-line or post-standard-therapy options according to guidelines. |
| Primary purpose or use | Studied for anti-tumor activity, safety, dose-limiting toxicity, and objective response rate in adults with KRAS G12D-mutant advanced solid tumors. | Chemotherapy regimens are used to control disease, improve survival, and manage symptoms in metastatic pancreatic cancer and advanced non-small cell lung cancer. |
| How treatment is given | ASP3082 is given by intravenous infusion, either alone or in combination protocols with other drugs, following trial-defined schedule and dose escalation/expansion procedures. Combination regimens match standard schedules for the additional agents. | Standard chemotherapy regimens are administered intravenously on established schedules (e.g., biweekly FOLFIRINOX, weekly nab-paclitaxel plus gemcitabine, platinum doublets every 3 weeks). |
| Evidence status in published literature | Early-phase clinical data show promising activity and safety in KRAS G12D-mutant NSCLC and pancreatic cancer, with ongoing investigation in NCT05382559. Peer-reviewed evidence is limited to preliminary efficacy and safety outcomes; long-term effectiveness remains unestablished. | High-quality published evidence and multiple randomized trials support efficacy of guideline-recommended chemotherapy regimens in metastatic pancreatic cancer and NSCLC; outcomes and limitations are well documented in external literature. |
| Important limitations | Study limitations include single-arm, non-randomized design, population heterogeneity, evolving dose levels, and cohort expansion; outcomes for ASP3082 remain preliminary pending longer follow-up and further randomized evaluation. | Standard chemotherapy regimens may have significant toxicity and limited benefit for KRAS G12D-mutant tumors, particularly in previously treated or resistant populations; no targeted approach currently addresses G12D mutation specifically. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant until suitable dose levels are identified
Small groups receive increasing doses of ASP3082 alone or with cetuximab via intravenous infusion to identify safe and tolerable dose levels.
Multiple visits during each 21-day cycle
Duration - Continues until stopping criteria are met
Participants receive ASP3082 alone or combined with other cancer therapies in 21- or 28-day cycles until intolerable side effects, disease progression, or participant decision.
Regular visits during each treatment cycle
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
11
Have more questions? Get in touch with our team for quick support
Wungki Park, Anup Kasi, Alexander I Spira...
https://pubmed.ncbi.nlm.nih.gov/41879829/Astellas Pharma Inc
Lead Sponsor